Library
SR-14968
Sold exclusively as a research chemical with no clinical trials in humans. Despite biased agonist properties in vitro, behaves more like a traditional opioid in vivo with respiratory depression at higher doses. Anecdotal reports describe slow onset (1-3 hours to peak), long duration (effects persisting 12-24 hours), and high potency. Naloxone reverses respiratory depression in animal models but human safety margins remain unverified. Very dangerous to redose before full onset.
Also known as: SR-14, SR-14968, 5,6-Dichloro brorphine
Classification
- Chemical: Benzimidazolone opioid
- Chemical: Opioid
- Psychoactive: Depressant
- Tag: Benzimidazole
- Tag: Habit-Forming
- Tag: Orphine
- Tag: Piperidine
- Tag: Research-Chemical
Effects
- Pain Relief
- Physical Euphoria
- Sedation
- Respiratory Depression
- Itchiness
- Pupil Constriction
- Cognitive Euphoria
- Compulsive Redosing
- Withdrawal
- Euphoria
- Anxiety Suppression
- Craving Suppression
- Dulled Perception
- Internal Hallucination
- Size Distortion
- Warmth
- Warm Flush
- Appetite Suppression
Routes of Administration
Oral
Dosage
- Threshold: 15–25 mg
- Light: 10-25 mg
- Common: 75–150 mg
- Strong: 150–250 mg
- Heavy: 250 mg+
Duration
- Onset: 0.5-1.5 h
- Comeup: 1-2 h
- Peak: 3-6 h
- Offset: 6-12 h
- After Effects: 12-24 h
- Total Duration: 6-12 h
Sublingual
Dosage
- Heavy: 50 mg+
- Light: 5–10 mg
- Common: 10–25 mg
- Strong: 25–50 mg
- Threshold: 3–5 mg
Duration
No data available for this section yet.
Harm Reduction
Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.
Sources
Substance data is aggregated from the following public harm-reduction and reference sources.
Links
This static page is intended as a readable non-JS and prerender-friendly library export.
